BridgeBio Pharma Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BBIO$74.29+0.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| March 31, · December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| (Unaudited) | (1) | |||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $475,222 | $375,935 | ||
| Marketable securities | 44,469 | — | ||
| Investments in equity securities | — | 58,949 | ||
| Receivables from licensing and collaboration agreements | 235,494 | 1,751 | ||
| Restricted cash | 131 | 16,653 | ||
| Prepaid expenses and other current assets | 28,108 | 24,305 | ||
| Total current assets | 783,424 | 477,593 | ||
| Property and equipment, net | 11,414 | 11,816 | ||
| Operating lease right-of-use assets | 8,052 | 8,027 | ||
| Intangible assets, net | 25,721 | 26,319 | ||
| Other assets | 20,722 | 22,625 | ||
| Total assets | $849,333 | $546,380 | ||
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||||
| Current liabilities: | ||||
| Accounts payable | $4,728 | $10,655 | ||
| Accrued compensation and benefits | 32,395 | 57,370 | ||
| Accrued research and development liabilities | 40,933 | 29,765 | ||
| Operating lease liabilities, current portion | 4,544 | 4,128 | ||
| Deferred revenue, current portion | 13,957 | 6,096 | ||
| Accrued professional and other accrued liabilities | 44,920 | 35,830 | ||
| Total current liabilities | 141,477 | 143,844 | ||
| 2029 Notes, net | 737,392 | 736,905 | ||
| 2027 Notes, net | 543,823 | 543,379 | ||
| Term loan, net | 434,717 | 446,445 | ||
| Operating lease liabilities, net of current portion | 8,297 | 8,981 | ||
| Deferred revenue, net of current portion | 19,890 | 3,727 | ||
| Other long-term liabilities | 595 | 5,634 | ||
| Total liabilities | 1,886,191 | 1,888,915 | ||
| Commitments and contingencies (Note 8) | ||||
| Redeemable convertible noncontrolling interests | 525 | 478 | ||
| Stockholders’ deficit: | ||||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — | ||
| Common stock, $0.001 par value; 500,000,000 shares authorized; 193,314,505 shares issued and 187,122,744 shares outstanding as of March 31, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023 | 193 | 181 | ||
| Treasury stock, at cost; 6,191,761 shares as of March 31, 2024 and December 31, 2023 | (275,000) | (275,000) | ||
| Additional paid-in capital | 1,820,994 | 1,481,032 | ||
| Accumulated other comprehensive income | 2 | 31 | ||
| Accumulated deficit | (2,595,717) | (2,560,501) | ||
| Total BridgeBio stockholders’ deficit | (1,049,528) | (1,354,257) | ||
| Noncontrolling interests | 12,145 | 11,244 | ||
| Total stockholders’ deficit | (1,037,383) | (1,343,013) | ||
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $849,333 | $546,380 | ||
(1)
The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.